Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors

Behavioural Brain Research

Volumn 213, Issue 2, 2010, Pages 225-229

  Soares, Vanessa de Paula ^b,c   Campos, Alline Cristina ^a   Bortoli, Valquíria Camin de ^a   Zangrossi, Hélio ^a   Guimarães, Francisco Silveira ^a   Zuardi, Antonio Waldo ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Neuroscience and Behavioral Sciences   (Brazil)

^c Federal University of Rio Grande do Nortem Campus Natal   (Brazil)

Author keywords

5 HT1A; Anxiety; Cannabidiol; DPAG; Electrical stimulation; Elevated T maze; Panic

Indexed keywords

CANNABIDIOL; SEROTONIN 1A RECEPTOR; N-(2-(4-(2-METHOXYPHENYL)-1-PIPERAZINYL)ETHYL)-N-(2-PYRIDINYL)CYCLOHEXANECARBOXAMIDE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN 1 AGONIST; SEROTONIN 1 ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANNULA; CONTROLLED STUDY; ELECTROSTIMULATION; ESCAPE BEHAVIOR; GENE ACTIVATION; MALE; MAZE TEST; NONHUMAN; OPEN FIELD TEST; PANIC; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; RAT; ANIMAL; ANIMAL MODEL; DRUG EFFECTS; MICROINJECTION; PHYSIOLOGY; WISTAR RAT;

ANIMALS; CANNABIDIOL; ELECTRIC STIMULATION; MALE; MAZE LEARNING; MICROINJECTIONS; MODELS, ANIMAL; PANIC; PERIAQUEDUCTAL GRAY; PIPERAZINES; PYRIDINES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS;

EID: 77953917373     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.05.004     Document Type: Article

References (54)

1. Bandler R., Shipley M.T. Columnar organization in the midbrain periaqueductal gray: modules for emotional expression?. Trends Neurosci 1994, 17(9):379-389. [Review].
2. Beckett S., Marsden C.A. The effect of central and systemic injection of the 5-HT1A receptor agonist 8-OHDPAT and the 5-HT1A receptor antagonist WAY100635 on periaqueductal grey-induced defence behaviour. J Psychopharmacol 1997, 11(1):35-40.
3. Beckett S.R., Lawrence A.J., Marsden C.A., Marshall P.W. Attenuation of chemically induced defence response by 5-HT1 receptor agonists administered into the periaqueductal gray. Psychopharmacology 1992, 108(1-2):110-114.
4. Bisogno T., Hanus L., De Petrocellis L., Tchilibon S., Ponde D.E., Brandi I., et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001, 134(4):845-852.
5. Campos A.C., Guimarães F.S. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology 2008, 199(2):223-230.
6. Campos A.C., Guimarães F.S. Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(8):1517-1521.
7. Carlini E.A., Leite J.R., Tannhauser M., Berardi A.C. Letter: cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents. J Pharm Pharmacol 1973, 25(8):664-665.
8. Carrier E.J., Auchampach J.A., Hillard C.J. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 2006, 103(20):7895-7900.
9. de Bortoli V.C., Nogueira R.L., Zangrossi H. Effects of fluoxetine and buspirone on the panicolytic-like response induced by the activation of 5-HT1A and 5-HT2A receptors in the rat dorsal periaqueductal gray. Psychopharmacology (Berl) 2006, 183(4):422-428.
10. de Bortoli V.C., Nogueira R.L., Zangrossi H. Alprazolam potentiates the antiaversive effect induced by the activation of 5-HT(1A) and 5-HT (2A) receptors in the rat dorsal periaqueductal gray. Psychopharmacology (Berl) 2008, 198(3):341-349.
11. de Paula Soares V., Zangrossi H. Involvement of 5-HT1A and 5-HT2 receptors of the dorsal periaqueductal gray in the regulation of the defensive behaviors generated by the elevated T-maze. Brain Res Bull 2004, 64(2):181-188.
12. de Paula Soares V., Zangrossi Stimulation of 5-HT1A or 5-HT2A receptors in the ventrolateral periaqueductal gray causes anxiolytic-, but not panicolytic-like effect in rats. Behav Brain Res 2009, 197(1):178-185.
13. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258(5090):1946-1949.
14. Fusar-Poli P., Crippa J.A., Bhattacharyya S., Borgwardt S.J., Allen P., Martin-Santos R., et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 2009, 66(1):95-105.
15. Graeff F.G. Brain defense systems and anxiety. Handbook of anxiety: the neurobiology of anxiety 1990, vol. 3:307-354. Elsevier Science Publishers, Amsterdam.
16. Graeff F.G. Serotonin, the periaqueductal gray and panic. Neurosci Biobehav Rev 2004, 28(3):239-259. [Review].
17. Graeff F.G., Silveira M.C., Nogueira R.L., Audi E.A., Oliveira R.M. Role of the amygdala and periaqueductal gray in anxiety and panic. Behav Brain Res 1993, 58(1-2):123-131.
18. Graeff F.G., Netto C.F., Zangrossi H. The elevated T-maze as an experimental model of anxiety. Neurosci Biobehav Rev 1998, 23(2):237-246. [Review].
19. Graeff F.G., Silva M., Del Ben C.M., Zuardi A.W., Hetem L.A., Guimarães F.S. Comparison between two models of experimental anxiety in healthy volunteers and panic disorder patients. Neurosci Biobehav Rev 2001, 25(7-8):53-59.
20. Guimarães F.S., Chiaretti T.M., Graeff F.G., Zuardi A.W. Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology 1990, 100(4):558-559.
21. Izzo A.A., Borrelli F., Capasso R., Di Marzo V., Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009, 30(10):515-527.
22. Jenck F., Moreau J.L., Martin J.R. Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity. Psychiatry Res 1995, 57(2):181-191.
23. Karniol I.G., Shirakawa I., Kasinski N., Pfeferman A., Carlini E.A. Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. Eur J Pharmacol 1974, 28(1):172-177.
24. Lastres-Becker I., Molina-Holgado F., Ramos J.A., Mechoulam R., Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 2005, 19(1-2):96-107.
25. Lemos J.I., Resstel L.B., Guimarães F.S. Involvement of the prelimbic prefrontal cortex on cannabidiol-induced attenuation of contextual conditioned fear in rats. Behav Brain Res 2010, 207(1):105-111.
26. Lovick T.A. Panic disorder-a malfunction of multiple transmitter control systems within the midbrain periaqueductal gray matter. Neuroscientist 2000, 6:48-59.
27. Magen I., Avraham Y., Ackerman Z., Vorobiev L., Mechoulam R., Berry E.M. Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT1A receptor activation. Br J Pharmacol 2010, 159(4):950-957.
28. Marseillan R.F. A solid state sine-wave stimulator. Physiol Behav 1977, 19(2):339-340.
29. Mechoulam R., Peters M., Murillo-Rodriguez E., Hanus L.O. Cannabidiol-recent advances. Chem Biodivers 2007, 4(8):1678-1692.
30. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995, 50(1):83-90.
31. Mechoulam R., Parker L.A., Gallily R. Cannabidiol: an overview of some pharmacological aspects. Chem Phys Lipids 2002, 121(1-2):35-43.
32. Mishima K., Hayakawa K., Abe K., Ikeda T., Egashira N., Iwasaki K., et al. Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. Stroke 2005, 36(5):1077-1082.
33. Monti J.M. Hypnotic-like effects of cannabidiol in the rat. Psychopharmacology 1977, 55(3):263-265.
34. Moreira F.A., Guimarães F.S. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol 2005, 512(2-3):199-205.
35. Moreira F.A., Aguiar D.C., Guimarães F.S. Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30(8):1466-1471.
36. Nashold, Wilson W.P., Slaughter D.G. Sensations evoked by stimulation in the midbrain of man. J Neurosurg 1969, 30(1):14-24.
37. Nogueira R.L., Graeff F.G. Role of 5-HT receptor subtypes in the modulation of dorsal periaqueductal gray generated aversion. Pharmacol Biochem Behav 1995, 52(1):1-6.
38. Norusis M.J. SPSS/PC+ advanced statistics, V2.0 1988, SPSS, Chicago.
39. Olds M.E., Olds J. Approach-escape interactions in rat brain. Am J Physiol 1962, 203:803-810.
40. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2007, Academic Press, London. 6th ed.
41. Poltronieri S.C., Zangrossi H., de Barros Viana M. Antipanic-like effect of serotonin reuptake inhibitors in the elevated T-maze. Behav Brain Res 2003, 147(1-2):185-192.
42. Resstel L.B., Joca S.R., Moreira F.A., Corrêa F.M., Guimarães F.S. Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats. Behav Brain Res 2006, 172(2):294-298.
43. Resstel L.B., Tavares R.F., Lisboa S.F., Joca S.R., Corrêa F.M., Guimarães F.S. 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol 2009, 156(1):181-188.
44. Russo E.B., Burnett A., Hall B., Parker K.K. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 2005, 30(8):1037-1043.
45. Schenberg L.C., Bittencourt A.S., Sudré E.C., Vargas L.C. Modeling panic attacks. Neurosci Biobehav Rev 2001, 25(7-8):647-659. [Review].
46. Teixeira R.C., Zangrossi H., Graeff F.G. Behavioral effects of acute and chronic imipramine in the elevated T-maze model of anxiety. Pharmacol Biochem Behav 2000, 65(4):571-576.
47. Thomas A., Baillie G.L., Phillips A.M., Razdan R.K., Ross R.A., Pertwee R.G. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 2007, 150(5):613-623.
48. Thomas B.F., Gilliam A.F., Burch D.F., Roche M.J., Seltzman H.H. Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 1998, 285(1):285-292.
49. Viana M.B., Tomaz C., Graeff F.G. The elevated T-maze: a new animal model of anxiety and memory. Pharmacol Biochem Behav 1994, 49(3):549-554.
50. Zangrossi, Graeff F.G. Behavioral validation of the elevated T-maze, a new animal model of anxiety. Brain Res Bull 1997, 44(1):1-5.
51. Zanoveli J.M., Nogueira R.L., Zangrossi Serotonin in the dorsal periaqueductal gray modulates inhibitory avoidance and one-way escape behaviors in the elevated T-maze. Eur J Pharmacol 2003, 473(2-3):153-161.
52. Zuardi A.W., Shirakawa I., Finkelfarb E., Karniol I.G. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 1982, 76(3):245-250.
53. Zuardi A.W., Antunes Rodrigues J., Cunha J.M. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology 1991, 104:260-264.
54. Zuardi A.W., Cosme R.A., Graeff F.G., Guimarães F.S. Effects of ipsapirone and cannabidiol on human experimental anxiety. J Psychopharmacol 1993, 7(1):82-88.